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Abstract
Carriers of pathogenic variants in CDKN2A have a 70% life-time risk of developing melanoma and 15–20% risk of develop-
ing pancreatic cancer (PC). In the Netherlands, a 19-bp deletion in exon 2 of CDKN2A (p16-Leiden mutation) accounts for 
most hereditary melanoma cases. Clinical experience suggests variability in occurrence of melanoma and PC in p16-Leiden 
families. Thereby, the risk of developing cancer could be modified by both environmental and genetic contributors, sug-
gesting that identification of genetic modifiers could improve patients’ surveillance. In a recent genome-wide association 
study (GWAS), rs36115365-C was found to significantly modify risk of PC and melanoma in the European population. This 
SNP is located on chr5p15.33 and has allele-specific regulatory activities on TERT expression. Herein, we investigated the 
modifying capacities of rs36115365-C on PC and melanoma in a cohort of 283 p16-Leiden carriers including 29 diagnosed 
with PC, 171 diagnosed with melanoma, 21 diagnosed with both PC and melanoma and 62 with neither PC nor melanoma. 
In contrast to previously reported findings, we did not find a significant association of PC risk with risk variant presence 
as determined by Generalized Estimating Equations (GEE) modelling. Interestingly, carrier-ship of the risk variant had a 
significant protective effect for melanoma (OR − 0.703 [95% CI − 1.201 to − 0.205], p = 0.006); however, the observed 
association was no longer significant after exclusion of probands to assess possible influence of ascertainment. Collectively, 
genetic modifiers for the prediction of PC and melanoma risk in p16-Leiden carriers remain to be determined.
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Introduction
CDKN2A is the major high-risk susceptibility gene identified 
thus far for familial melanoma [1]. In the Netherlands, the most 
common cause of familial melanoma is a CDKN2A founder 
mutation which is a deletion of 19 bp in exon 2 (c.225_243del, 
p.(A76Cfs*64); RefSeq NM_000077.4), also known as the 
p16-Leiden mutation resulting in inactivation of tumor-sup-
pressive properties of p16(INK4a) [2]. Carriers have a lifetime 
risk of 70% to develop melanoma [3], and a life-time risk of 
15–20% to develop pancreatic cancer (PC) [4–6].
PC is a highly aggressive cancer subtype with very poor 
prognosis resulting in a 5-year survival rate of < 5% [7]. 
It is therefore one of the leading causes of cancer-related 
deaths worldwide [8], suggesting there is much to gain by 
early detection of PC at a stage when surgical removal is 
still curative [9]. Carriers of the p16-Leiden mutation are 
advised to undergo screening yearly for PC using MRI from 
the age of 45 [6].
Clinical studies of p16-Leiden mutated families, have 
shown variability in occurrence of melanoma and PC among 
families suggesting contribution of modifying factors to can-
cer risk [4]. For example, genetic risk factors such as MC1R, 
were found to modify risk of developing melanoma in 
p16-Leiden positive families significantly [10, 11]. Therefore, 
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the variable occurrence of PC in those families might also 
be explained by modifying genetic risk factors other than the 
p16-Leiden mutation. Determination of those factors would 
allow for a better identification of patients at increased risk 
that might benefit from personalized clinical management.
In an attempt to identify genetic factors that modulate 
the risk of pancreatic cancer in p16-Leiden carriers, Potjer 
et al. analyzed seven SNPs associated with PC risk in the 
general population in this cohort of carriers and found 
no significant association [12]. Recently a risk variant, 
rs36115365-C, was identified to be significantly correlated 
with PC risk in the European population [13]. This SNP is 
located at a multi-cancer risk locus on chr5p15.33 and was 
found to have allele-specific regulatory activities on TERT 
expression, mutations of which have been associated with 
melanoma risk [14]. These data suggest that variation within 
rs36115365 (G,C) could contribute to cancer development. 
Indeed, carriers of the minor C-allele are at increased risk of 
pancreatic cancer (RR = 1.2). Remarkably at the same time, 
carriers of this C-allele are at diminished risk of developing 
melanoma [13]. Several risk variants have been reported to 
be associated with a small but important protective effect 
against melanoma in sporadic melanoma such as variants in 
GSTM1 and GSTT1 [15] and polymorphisms in the Vitamin 
D receptor gene [16]. These findings collectively suggest 
that identification of genetic modifiers in p16-Leiden carriers 
could be used to estimate the risk of developing PC and mel-
anoma more accurately. This study therefore, investigates 
and verifies the risk impact of the reported SNP variant, 
rs36115365-C in a Dutch p16-Leiden positive patient cohort.
Methods
Cohort description
The study population included only confirmed p16-Leiden 
carriers of which DNA samples were available from the 
Laboratory for Diagnostic Genome Analysis (LDGA) of 
Leiden University Medical Center (LUMC). Subject-specific 
clinical information was collected between 1998 and the 1st 
of January, 2015. Cases of PC were individuals carrying 
the p16-Leiden mutation who were diagnosed with primary 
exocrine PC. Similarly, cases of melanoma were p16-Leiden 
carriers who were diagnosed with cutaneous (multiple) mel-
anoma. Detailed medical record data on the study population 
has been reported previously [12]. Approval of this study 
was obtained from the ethics committee of Leiden Univer-
sity Medical Center (LUMC #P14.148) [12].
In total, 419 p16-Leiden carriers were available for inclu-
sion in the current study. The comparative analysis was for-
mulated by filtering for carriers diagnosed with PC, carri-
ers diagnosed with melanoma, and a group who did neither 
develop PC nor melanoma but were older than 55 years 
of age. Subsequently, a master cohort of 283 p16-Leiden 
carriers from a total of 121 p16-Leiden families were 
included. These consisted of 29 carriers with PC (median 
age 47 years), 171 with melanoma (median age 60), 21 with 
both PC and melanoma (median age 60) and 62 with neither 
PC nor melanoma (median age 71) (Table 1).
Genotyping and statistical analysis
Genotyping analysis was carried out using the rhAmp-SNP 
Genotyping Assay (Integrated DNA Technologies (IDT), 
Leuven, Belgium). Bi-allelic discrimination was achieved by 
incorporation of two forward primers specifically targeting 
the allele of interest (rs36115365-C). The genotyping pro-
cedure was performed according to manufacturer’s instruc-
tions. The reference allele was labelled with FAM reporter 
dye and the alternate allele with Yakima Yellow (YY) 
reporter dye which were both detected on CFX384 Touch 
Real-Time PCR Detection System (Bio-Rad, Veenendaal, 
The Netherlands) with excitation sources and emission fil-
ters for respective wavelengths. The minor allele frequency 
(MAF) was calculated based on Hardy–Weinberg law. For 
Table 1  Master cohort characteristics of p16-Leiden carriers
*p16-Leiden carriers who developed either pancreatic cancer or melanoma or neither of the two and were older than 55 years of age served as 
controls in comparative analysis, see Tables 2 and 3
p16-Leiden carriers (N = 283)
Pancreatic cancer 
(N = 29)*
Melanoma (N = 171)* Pancreatic cancer and mela-




Median age (years) 47 (21–72) 60 (27–93) 60 (42–78) 71 (55–86)
Gender (M:F) 9:20 71:100 8:13 26:36
Multiple melanoma – 71/171 (42%) 6/21 (29%) –
Patients diagnosed with 
other cancer
3 33 6 24
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statistical analysis, a generalized linear model with logit link 
was used to assess the association between alternate-allele 
presence and risk for PC and melanoma development. The 
binary dependent variable was either PC or melanoma and 
SNP variant was the explanatory indicator variable. Regres-
sion coefficients and 95% Confidence Intervals (CI) were 
calculated. P-values of < 0.05 were considered statistically 
significant.
Due to nature of this family-based study, individuals are 
not independent, they are clustered. In order to account for 
this feature, a Generalized Estimating Equations (GEE) pro-
cedure was used to fit the model. The GEE procedure allows 
to deal with clustered data. Since the specific correlation 
structure of this data is difficult to estimate due to the small 
sample size, an independence working correlation structure 
was assumed. To avoid the impact of possible misspecifica-
tion of the model in the confidence intervals and p-values, 
robust estimates of the standard errors were obtained using 
a sandwich estimator [17]. All statistical analyses were per-
formed using IBM SPSS Statistics 23.
Results
The risk impact of rs36115365-C on PC was calculated by 
comparing a total of 50 p16-Leiden carriers who developed 
PC (median age 50) to 143 controls (median age 74) consist-
ing of 62 carriers who did not develop PC and 81 carriers 
who developed melanoma but were older than 55 years of 
age (sub-cohort characteristics, Table 2). Similarly, the risk 
impact of rs36115365-C on melanoma was calculated by 
comparing a total of 192 p16-Leiden carriers who developed 
melanoma (median age 60) to 73 controls (median age 71), 
consisting of 62 carriers who did not develop melanoma and 
11 carriers who developed PC but were older than 55 years 
of age (sub-cohort characteristics, Table 3). The latter group 
in both analyses was treated as a control since it consisted of 
p16-Leiden carriers older than 55 years of age with a sub-
sequent reduced risk of developing melanoma or pancreatic 
carcinoma in the future.
MAF of the risk variant rs36115365-C for different com-
parison groups, Beta values and 95% CI were calculated 
(Table 4). No significant association was found for risk 
variant presence and PC risk (Table 4). Interestingly, a sig-
nificant negative association was observed for risk variant 
carriers and melanoma development suggesting a protective 
effect of rs36115365-C for melanoma in p16-Leiden carriers 
(OR − 0.703, 95% CI (− 1.201, − 0.205), p-value = 0.006) 
(Table 4). To assess possible influence of ascertainment 
in the sample cohort, the association with melanoma was 
further explored by excluding probands. This resulted in 
a decreased cohort size of 69 families consisting of 158 
p16-Leiden carriers, 85 of whom had developed melanoma. 
The statistical significant association did not remain in that 
case for risk variant carriers (GEE model − 0.453, 95% CI 
(− 1.051, 0.145), p-value = 0.138).
Discussion
Identification of genetic modifiers for PC and melanoma risk 
in p16-Leiden carriers could possibly explain the variability 
of cancer occurrence within p16-Leiden positive families 
and ultimately favor individualized surveillance and clini-
cal management of those patients [4, 12]. Herein, we sought 
to estimate the risk of developing PC and melanoma more 
accurately in carriers of the pathogenic variant p16-Lei-
den. This was tested by determining whether a previously 
published associated risk variant for PC and melanoma, 
Table 2  Sub-cohort 
characteristics of p16-Leiden 
carriers with/without pancreatic 
cancer





Median age (years) 50 (21–78) 74 (55–93)
Gender (M/F) 17/33 60/83
Medical history of melanoma 21 81
Multiple melanoma 6/21 (29%) 37/81 (46%)
Patients diagnosed with other cancer 9 51
Table 3  Sub-cohort characteristics of p16-Leiden carriers with/with-
out melanoma
Melanoma 




Median age (years) 60 (27–93) 71 (55–86)
Gender (M/F) 79/113 28/45
Medical history of pancreatic 
cancer
21 11
Multiple melanoma 77/192 (40%) –
Patients diagnosed with other 
cancer
54 24
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rs36115365-C [13], could explain modified risk in a homo-
geneous population of p16-Leiden carriers.
The MAF of rs36115365-C in the general European 
(Non-Finnish) population is 0.18 [18] and in the Nether-
lands specifically, it is 0.20 [19] indicating a common vari-
ant with high chances of detection. In this case, the second 
most-common allele (C) was detected with MAFs ranging 
from 0.21 to 0.29 in 283 p16-Leiden carriers, slightly higher 
than in the general population. A limitation of this study 
however is the small cohort size that could limit possibili-
ties of detecting statistical associations. Moreover, selecting 
subjects older than 55 years of age not only reduced the 
control group size but also the possibility of developing PC 
or melanoma in the future was not fully excluded. A GEE 
statistical procedure was applied as it is appropriated for 
studying family based associations [17, 20]. There was no 
significant association between rs36115365-C presence and 
PC risk in p16-Leiden carriers.
Several efforts in scientific literature focused on identify-
ing genetic modifiers of PC risk in CDKN2A-mutation carri-
ers. Yang et al., applied Whole Exome Sequencing (WES) in 
66 PC patients with/without a CDKN2A mutation [21]. The 
combined data from five research groups, including 13 pan-
creatic CDKN2A mutated (p16-Leiden) cases from the Neth-
erlands identified 35 variants in PC-related genes. Nominally 
significant associations were obtained for mismatch repair 
genes (MLH1, MSH2, MSH6, PMS2) in all PC patients, how-
ever, variants in ATM, CPA1, and PMS2 were only observed 
in CDKN2A wild-type PC patients. Further, nine CDKN2A 
mutated and four CDKN2A wild-type PC patients had rare 
potentially deleterious variants in multiple PC-related genes. 
These results, therefore, suggest that a subset of PC patients 
may have increased risk because of germline mutations in 
multiple PC-related genes [21]. Nonetheless, p16-Leiden 
carriers described in the study by Yang were not included 
in the current study. In addition, the same group showed that 
sequencing analysis of PALB2, another high susceptibility 
gene for PC, did not reveal any deleterious mutations in PC 
patients from CDKN2A-mutated families [22]. Potjer et al. 
who studied the same cohort of p16-Leiden carriers as in 
the current study, did not identify an association of seven 
PC-associated SNPs with PC risk [12]. Therefore, consid-
eration of other genetic modifiers yet unknown could be an 
additional explanation of the variability in occurrence of PC 
within p16-Leiden families. Moreover, epidemiological stud-
ies suggest that non-genetic factors may also contribute to 
PC development specifically in p16-Leiden carriers, with the 
most significant one being smoking [23] as well as alcohol 
use and obesity in the general population [24]. Collectively 
these data suggest that rs36115365-C risk variant could not 
be used to estimate the risk of PC in p16-Leiden mutation 
carriers more accurately unlike in the European population 
published previously [13].
Modifier genes for melanoma have been well described 
in literature for CDKN2A mutation carriers [10, 11, 25, 26]. 
The variant rs36115365-C, previously published to be nega-
tively correlated with melanoma risk [13] had a significantly 
negative association with melanoma development in this 
study. This effect did not remain however, when excluding 
probands from the analysis suggesting that ascertainment of 
melanoma cases influenced the results.
Conclusion
Here, no significant association was found between 
rs36115365-C presence and risk of PC development in 
p16-Leiden carriers in contrast to previous published litera-
ture in the European population. Reversely, a statistically 
significant protective effect was determined for melanoma 
risk in the same cohort of p16-Leiden carriers, an effect that 
lost significance when excluding melanoma probands. Col-
lectively, genotyping and statistical data suggest that genetic 
modifiers for the prediction of PC and melanoma in p16-Lei-
den carriers remain to be determined.
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Table 4  Association of 
rs36115365-C presence with PC 
and melanoma in p16 –Leiden 
carriers
Pancreatic cancer MAF rs36115365 (G,C) Allelic OR 95% CI p-value
Cases Controls
Pancreatic cancer 0.23 0.23 − 0.027 − 0.804 0.750 0.946
Melanoma 0.21 0.29 − 0.703 − 1.201 − 0.205 0.006
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